A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer
- 30 September 2004
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 45 (3) , 387-392
- https://doi.org/10.1016/j.lungcan.2004.02.017
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell CarcinomaInvestigational New Drugs, 2001
- A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with ChemotherapyInvestigational New Drugs, 2001
- Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2000
- Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A ReviewJournal of Clinical Oncology, 2000
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agentsInvestigational New Drugs, 1996
- Acylfulvenes, a new class of potent antitumor agentsCellular and Molecular Life Sciences, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995